Aerie Pharmaceuticals Inc (AERI:NASDAQ) Annual Reports & Investor Relations Material

Overview

Aerie Pharmaceuticals is a company that specializes in the development of pharmaceutical products for the treatment of glaucoma and other eye diseases. Its most promising products are Rhopressa and Roclatan, both of which are once-daily eye drops that reduce intraocular pressure in patients with glaucoma or ocular hypertension. Rhopressa is currently in Phase III registration trials, while Roclatan has completed a Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension. The company is focused on bringing these innovative therapies to market, with the ultimate goal of improving the lives of those suffering from these conditions.

Frequently Asked Questions

What is Aerie Pharmaceuticals Inc's ticker?

Aerie Pharmaceuticals Inc's ticker is AERI

What exchange is Aerie Pharmaceuticals Inc traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Aerie Pharmaceuticals Inc's headquarters?

They are based in Durham, North Carolina

How many employees does Aerie Pharmaceuticals Inc have?

There are 501-1000 employees working at Aerie Pharmaceuticals Inc

What is Aerie Pharmaceuticals Inc's website?

It is http://www.aeriepharma.com/

What type of sector is Aerie Pharmaceuticals Inc?

Aerie Pharmaceuticals Inc is in the Healthcare sector

What type of industry is Aerie Pharmaceuticals Inc?

Aerie Pharmaceuticals Inc is in the Drug Manufacturers - Major industry

Who are Aerie Pharmaceuticals Inc's peers and competitors?

The following five companies are Aerie Pharmaceuticals Inc's industry peers:

- Boston Properties

- Alimera Sciences

- Astellas Pharma, Inc.

- Advanz Pharma Corp

- Merck & Co